Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001192482-20-000311
Filing Date
2020-05-04
Accepted
2020-05-04 17:12:59
Documents
1
Period of Report
2020-04-23

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT edgar.html 3  
1 PRIMARY DOCUMENT edgar.xml 3 3164
  Complete submission text file 0001192482-20-000311.txt   4695
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Issuer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2614 BOSTON POST ROAD, SUITE 33B GUILFORD CT 06437
Business Address 2614 BOSTON POST ROAD, SUITE 33B GUILFORD CT 06437 203-643-8060
BioXcel Holdings, Inc. (Reporting) CIK: 0001811154 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38410 | Film No.: 20845817